Sana Biotechnology Presents Preclinical Data on In Vivo CAR-T Approach
Event summary
- Sana Biotechnology will present oral preclinical data at the ASGCT 2026 Annual Meeting on May 12, 2026.
- The presentation focuses on SG293, an in vivo CAR T product candidate targeting CD19.
- SG293 utilizes Sana’s proprietary fusogen-based delivery technology to target CD8+ T cells.
- The data suggests SG293 may avoid off-target effects associated with traditional CAR-T therapies.
The big picture
Sana’s in vivo CAR-T approach represents a significant shift in gene therapy development, aiming to overcome limitations of ex vivo manufacturing and reduce toxicity. The focus on cell-specific delivery with fusogens is a novel strategy to improve CAR-T safety and expand potential applications to autoimmune diseases. While the preclinical data is promising, the inherent complexities of in vivo gene delivery pose substantial technical and regulatory hurdles.
What we're watching
- Delivery Efficacy
- The specificity of Sana’s fusogen technology to CD8+ T cells will be critical for demonstrating safety and efficacy, and any deviations from the presented data could raise concerns about off-target effects.
- Clinical Translation
- The transition from non-human primate (NHP) data to human clinical trials will need to demonstrate consistent results, as in vivo CAR-T therapies face unique challenges in translation.
- Competitive Landscape
- The success of SG293 will depend on its ability to differentiate from existing and emerging in vivo CAR-T approaches, particularly those utilizing alternative viral vectors.
Related topics